![](https://investorshub.advfn.com/uicon/3393.png?cb=1707411030)
Wednesday, February 14, 2024 5:39:13 PM
Cerecor and Aevi Genomic Medicine Merged Feb 2020
Cerecor rebranded into Avalo Therapeutics ticker AVTX
Avalo Therapeutics (formerly Cerecor) is developing AVTX 611 (formerly CERC 611)
November 2022 Avalo Therapeutics enters into an agreement with ES Therapeutics to sell its net economic rights to future payments of previously out-licensed assets including CERC 611
AVTX 611 got rebranded to ES 481 is being developed by ES Therapeutics for the treatment of Epilepsy.
Clinical development is underway in Australia and Canada.
Study Design
Total Participants: 24
Study Start date:
November 21, 2021
Estimated Completion Date:
December 31, 2023
This webpage mentions:
The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
https://www.sciencedirect.com/science/article/abs/pii/S000689931930410X
The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
Abstract
The need for improved antiepileptics is clearly mandated despite the existence of multiple existing medicines from different chemical and mechanistic classes. Standard of care agents do not fully control epilepsies and have a variety of side-effect and safety issues. Patients typically take multiple antiepileptic drugs and yet many continue to have seizures. Antiepileptic-unresponsive seizures are life-disrupting and life-threatening. One approach to seizure control is surgical resection of affected brain tissue and associated neural circuits. Although non-human brain studies can provide insight into novel antiepileptic mechanisms, human epileptic brain is the bottom-line biological substrate. Human epileptic brain can provide definitive information on the presence or absence of the putative protein targets of interest in the patient population, the potential changes in these proteins in the epileptic state, and the engagement of novel molecules and their functional impact in target tissue. In this review, we discuss data on two novel potential antiepileptic drugs. CERC-611 (LY3130481) is an AMPA receptor antagonist that selectively blocks AMPA receptors associated with the auxiliary protein TARP ?-8 and is in clinical development. KRM-II-81 is a positive allosteric modulator of GABAA receptors selectively associated with protein subunits a2 and a 3. Preclinical data on these compounds argue that patient-based biological data increase the probability that a newly discovered molecule will translate its antiepileptic potential to patients.
Recent AVTX News
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer • GlobeNewswire Inc. • 06/24/2024 08:01:00 PM
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit • GlobeNewswire Inc. • 06/17/2024 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/07/2024 11:01:10 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/06/2024 08:03:22 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/03/2024 11:20:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:01:22 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/13/2024 04:38:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:33:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:59 AM
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Avalo Reports 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/29/2024 08:01:00 PM
- Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million • GlobeNewswire Inc. • 03/27/2024 08:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 02:13:42 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:02:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:05:25 PM
- Avalo Therapeutics Announces 1-for-240 Reverse Stock Split • GlobeNewswire Inc. • 12/27/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:01:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:01:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/07/2023 12:02:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 12:01:08 PM
- Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split • GlobeNewswire Inc. • 12/07/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 12:15:21 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM